Company intelligence / Profile preview

Polaris AI Pharma

Hwaseong-si, Gyeonggi-do, South Korea

Ownership: Private
Employees: ~160
Development stage: Other

Overview

Polaris AI Pharma supplies approximately 40-80 types of active pharmaceutical ingredients (APIs) and intermediates, primarily for generic drugs for a variety of indications, distributed domestically and internationally, especially to Japan, with further plans to expand globally. No proprietary clinical trial data or results; focus is commercial manufacturing and supply of raw pharmaceutical ingredients.[1][3][4][8]

Therapeutic areas: ImmunologyEndocrinologyMetabolic DisordersOphthalmologyPsychiatryMen's HealthInfectious DiseasesGastroenterologyPulmonologyCardiovascularOncologyNeurology
Modalities: Small molecule
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Polaris AI Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polaris AI Pharma.

Explore the full profile